A 10 percent holder just added 643,850 MYNZ shares. In a low liquidity microcap, that nudges effective float lower and can change how price reacts to real news. Fewer shares available means bids have to chase higher on good updates, while offers thin out faster. That does not guarantee upside, but it does make tape responses more elastic.
Why it matters now: catalysts are lined up. AACR 2026 in April should show pancreatic verification data. eAArly DETECT 2 feasibility for CRC is guided to complete in the first half of 2026 ahead of the pivotal. Europe is the operating bridge with UK registration, Swiss approval plus a launch partner, and placement inside Germany’s DoctorBox. If ownership concentration rises while these hit, both breakouts and pullbacks can overshoot.
How I adapt: smaller entries, clear risk lines, and scale on strength rather than full size at once. I also track filings for more insider buys or 13D/13G changes, and watch volume vs 10 day to confirm that supply is tightening into catalysts.
Not financial advice. Do your own research.